- Home
- SKYE vs OGI Comparison
SKYE vs OGI Comparison
Compare SKYE & OGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- OGI
- Stock Information
- Founded
- SKYE 2012
- OGI 2013
- Country
- SKYE United States
- OGI Canada
- Employees
- SKYE N/A
- OGI N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- OGI Biotechnology: Pharmaceutical Preparations
- Sector
- SKYE Health Care
- OGI Health Care
- Exchange
- SKYE Nasdaq
- OGI Nasdaq
- Market Cap
- SKYE 73.4M
- OGI 176.7M
- IPO Year
- SKYE N/A
- OGI N/A
- Fundamental
- Price
- SKYE $3.74
- OGI $1.32
- Analyst Decision
- SKYE Buy
- OGI
- Analyst Count
- SKYE 6
- OGI 0
- Target Price
- SKYE $16.60
- OGI N/A
- AVG Volume (30 Days)
- SKYE 2.0M
- OGI 556.9K
- Earning Date
- SKYE 08-08-2025
- OGI 08-12-2025
- Dividend Yield
- SKYE N/A
- OGI N/A
- EPS Growth
- SKYE N/A
- OGI N/A
- EPS
- SKYE N/A
- OGI 0.10
- Revenue
- SKYE N/A
- OGI $135,031,829.00
- Revenue This Year
- SKYE N/A
- OGI $50.30
- Revenue Next Year
- SKYE N/A
- OGI $16.01
- P/E Ratio
- SKYE N/A
- OGI $13.00
- Revenue Growth
- SKYE N/A
- OGI 20.49
- 52 Week Low
- SKYE $1.14
- OGI $0.85
- 52 Week High
- SKYE $8.26
- OGI $2.08
- Technical
- Relative Strength Index (RSI)
- SKYE 66.59
- OGI 48.55
- Support Level
- SKYE $2.12
- OGI $1.25
- Resistance Level
- SKYE $5.75
- OGI $1.37
- Average True Range (ATR)
- SKYE 0.55
- OGI 0.06
- MACD
- SKYE 0.17
- OGI -0.01
- Stochastic Oscillator
- SKYE 45.82
- OGI 27.45
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.